TYVERB 250 mg, film-coated tablet 140 tablets
Active ingredients: Lapatinib ditosylate hydrate, Lapatinib
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet140 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- TYVERB 250 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- flacon(s) polyéthylène haute densité (PEHD) avec fermeture de sécurité enfant de 140 comprimé(s)
- Marketing authorisation holder
- NOVARTIS EUROPHARM (IRLANDE)
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 16 Apr 2012
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
65609052CIP74170182CIP133400941701825Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| DITOSILATE DE LAPATINIB MONOHYDRATÉcomprimé | — | SA |
| LAPATINIBcomprimé | 250 mg · un comprimé | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The published catalog does not list other packages of similar medicines.